EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

NCT03287609 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

308

Enrollment

OTHER

Sponsor class

Conditions

Acute Coronary Syndrome

Interventions

DRUG: Evolocumab 140 mg/mL
DRUG: Placebo

Sponsor

Insel Gruppe AG, University Hospital Bern

Collaborators

[object Object]
[object Object]